Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisantrene in Relapsed/Refractory AML
NCT03820908Phase 2Completed
- Sponsor
- Sheba Medical Center
- Start
- Jul 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bisantrene in acute myeloid leukemia (AML), sponsored by Sheba Medical Center. Primary endpoints: Overall Survival at 24 months and Leukemia-free Survival at 24 months. Started Jul 2019; status: completed.
02
Drugs
bisantrene
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03820908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820908.